Voyager Therapeutics (NASDAQ:VYGR) Shares Down 2.8%

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) shares traded down 2.8% on Monday . The company traded as low as $8.19 and last traded at $8.19. 77,180 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 940,609 shares. The stock had previously closed at $8.43.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. StockNews.com raised Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, March 9th. HC Wainwright began coverage on Voyager Therapeutics in a report on Tuesday, March 19th. They issued a "buy" rating and a $30.00 price objective on the stock. Citigroup initiated coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They set a "buy" rating and a $16.00 price target on the stock. Guggenheim initiated coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They set a "buy" rating and a $22.00 price objective for the company. Finally, Wells Fargo & Company upgraded Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $19.33.

Voyager Therapeutics Stock Down 2.3 %

The stock has a market cap of $447.44 million, a price-to-earnings ratio of 2.67 and a beta of 0.96. The firm's 50 day moving average is $8.78 and its two-hundred day moving average is $7.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.84. The firm had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. On average, analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently made changes to their positions in the company. Kestra Advisory Services LLC bought a new position in shares of Voyager Therapeutics in the third quarter valued at approximately $980,000. Ritholtz Wealth Management boosted its holdings in shares of Voyager Therapeutics by 11.8% in the fourth quarter. Ritholtz Wealth Management now owns 19,759 shares of the company's stock valued at $167,000 after acquiring an additional 2,089 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of Voyager Therapeutics in the third quarter valued at approximately $294,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Voyager Therapeutics in the fourth quarter valued at approximately $43,000. Finally, Aigen Investment Management LP bought a new position in shares of Voyager Therapeutics in the third quarter valued at approximately $109,000. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.